Limited (“the Company”) would like to clarify on the change in the performance and the financial status over 20 percent for Q2/2019 ended June 30, 2019 of the Company and its subsidiaries as shown below

account, bond dealing, private repos and other investments. The Company’s DW business was significantly impacted by the extreme volatility of the Thai stock market during March 2020. The Company is a market

วันที่ 15 ตุลาคม 2545 1 NO. (SUTHA-SET) 016/2019/EN 14 August 2019 Subject : Clarification of Q2/2019 the total revenues and the Net profit change more than 20% To : The President of the Stock

, 2017 as follow; Consolidated 3Q/2017 3Q/2016 Change Financial Statements (Million Baht) (%) (Million Baht) (%) (%) Revenue from Sales 1,405.2 100.0 % 1,261.0 100.0 % 11.4 % Cost of Sales (965.8) (68.7

granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change

market in the country last April. This caused problems for distribution channels of the Company’s customers, as they had to postpone their purchase orders of the Company’s products. As result, domestic

Baht Item Quarter Change (%) H1 Change 2/2017 1/2017 2/2016 1/2017 2/2016 2017 2016 (%) Interest Income Loans 22,166 21,828 21,797 1.5% 1.7% 43,994 44,172 (0.4)% Interbank and money market items 2,045

capital market situation, while fees from bancassurance and mutual fund services increased. Operating Expenses Million Baht Item Quarter Change (%) H1 Change 2/2019 1/2019 2/2018 1/2019 2/2018 2019 2018

Income Total Revenues (Million Baht) Quarterly Change Six-month End June 30, Change 2/2017 2/2016 % 2017 2016 % Revenue from sales Domestic sales 104.6 117.8 (11.2) 241.4 238.5 1.2 Export sales 391.0

demand in the market. Excess production in China caused extra problems as the local production could not be shipped out due to pandemic, resulting into an intense competition and price in China. For